Related references
Note: Only part of the references are listed.Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells involvement of PPAR-α
Shucun Qin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
George A. Diamond et al.
ANNALS OF INTERNAL MEDICINE (2007)
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetest
Charles M. Gerrits et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Coronary heart disease outcomes in patients receiving antidiabetic agents
Andrew T. McAfee et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure
Henry J. Dargie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke - Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
Robert Wilcox et al.
STROKE (2007)
Anti-inflammatory effects of pioglitazone and/or sinivastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein -: The PIOSTAT study
Markolf Hanefeld et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Adjudication of serious heart failure in patients from PROactive
Lars Ryden et al.
LANCET (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
CIRCULATION (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effect of various diuretic treatments on rosiglitazone-induced fluid retention
Janaka Karalliedde et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
Maria Mori Brooks et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in Type 2 diabetic patients:: a randomized study
H Shimizu et al.
DIABETIC MEDICINE (2006)
Pioglitazone reduces neointima volume after coronary stent implantation -: A randomized, placebo-controlled, double-blind trial in nondiabetic patients
N Marx et al.
CIRCULATION (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2
T Forst et al.
MICROCIRCULATION (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention
H Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus -: Results from a controlled randomized study
MR Langenfeld et al.
CIRCULATION (2005)
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure - An observational study
FA Masoudi et al.
CIRCULATION (2005)
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
J Danesh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
AR Diani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes
A Hsiao et al.
BIOINFORMATICS (2004)
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes
D Choi et al.
DIABETES CARE (2004)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus
JS Sidhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells
GZ Hong et al.
FASEB JOURNAL (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - The JNC 7 Report
AV Chobanian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease
N Marx et al.
CIRCULATION (2003)
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial
AE Caballero et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men -: Results from the MONICA Augsburg Cohort Study, 1984-1998
B Thorand et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects
D Tripathy et al.
DIABETES (2003)
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
MS Sutton et al.
DIABETES CARE (2002)
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
SM Haffner et al.
CIRCULATION (2002)
PPAR activators as antiinflammatory mediators in human T lymphocytes -: Implications for atherosclerosis and transplantation-associated arteriosclerosis
N Marx et al.
CIRCULATION RESEARCH (2002)
Impact of Troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus
T Takagi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat
T Tsuji et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2001)
Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides
Y Fukunaga et al.
ATHEROSCLEROSIS (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes
M Emoto et al.
DIABETES (2001)
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
LS Phillips et al.
DIABETES CARE (2001)
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus - A serial intravascular ultrasound study
T Takagi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
JM Olefsky
JOURNAL OF CLINICAL INVESTIGATION (2000)
Peroxisome proliferator-activate inhibit development of atherosclerosis in LDL receptor-deficient mice
AC Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
N Marx et al.
JOURNAL OF IMMUNOLOGY (2000)
Mechanism of troglitazone action in type 2 diabetes
KF Petersen et al.
DIABETES (2000)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
V Pasceri et al.
CIRCULATION (2000)
Share Paper
